Jasper Financial Statements From 2010 to 2025

JSPRW Stock  USD 0.14  0.01  7.69%   
Jasper Therapeutics financial statements provide useful quarterly and yearly information to potential Jasper Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Jasper Therapeutics financial statements helps investors assess Jasper Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Jasper Therapeutics' valuation are summarized below:
Earnings Share
(3.84)
There are over one hundred nineteen available fundamental trends for Jasper Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should confirm Jasper Therapeutics' regular fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to climb to about 294.7 M in 2025. Enterprise Value is likely to climb to about 228.7 M in 2025
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 13.1 M or Other Operating Expenses of 40 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.31. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Jasper Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets67.4 M79.9 M42.5 M
Slightly volatile
Other Current Liabilities5.1 M10.1 M2.8 M
Slightly volatile
Total Current Liabilities8.9 M15.2 M4.7 M
Slightly volatile
Net Tangible Assets73 M75.9 M91.7 M
Slightly volatile
Warrants69 M71.4 M86.8 M
Slightly volatile
Accounts Payable2.9 MM1.5 M
Slightly volatile
Cash60.2 M71.6 M39.6 M
Slightly volatile
Non Current Assets Total4.6 M4.1 M1.9 M
Slightly volatile
Non Currrent Assets Other1.1 M1.2 M460 K
Slightly volatile
Cash And Short Term Investments60.2 M71.6 M39.6 M
Slightly volatile
Common Stock Total Equity447524398
Slightly volatile
Short Term Investments80.1 M90.1 M98.3 M
Slightly volatile
Liabilities And Stockholders Equity66.6 M79.9 M39.9 M
Slightly volatile
Non Current Liabilities Total2.8 MM7.6 M
Pretty Stable
Capital Surpluse9.4 M13.9 M7.6 M
Slightly volatile
Other Current Assets2.4 M4.2 M1.1 M
Slightly volatile
Total Liabilities17.6 M18.2 M10.4 M
Slightly volatile
Long Term Investments110.3 M115.4 M101.8 M
Slightly volatile
Total Current Assets62.7 M75.8 M40.6 M
Slightly volatile
Non Current Liabilities Other1.9 MMM
Slightly volatile
Common Stock2.9 KK7.2 K
Slightly volatile
Short and Long Term Debt Total2.8 M1.8 MM
Slightly volatile
Property Plant And Equipment Net4.3 M2.9 M2.7 M
Slightly volatile
Long Term Debt10.5 M11.8 M12.9 M
Slightly volatile
Net Receivables412.2 K225 K543.6 K
Slightly volatile
Common Stock Shares Outstanding15.3 M14.6 MM
Slightly volatile
Long Term Debt Total10.5 M11.8 M12.9 M
Slightly volatile
Capital Lease Obligations2.8 M1.8 MM
Slightly volatile
Property Plant And Equipment Gross5.6 M6.7 M3.2 M
Slightly volatile
Capital Stock1.9 KK1.5 K
Slightly volatile
Net Working Capital59 M60.6 M30.9 M
Slightly volatile
Current Deferred Revenue2.2 M2.5 M2.8 M
Slightly volatile
Short Term Debt960.2 K1.1 M1.1 M
Pretty Stable

Jasper Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M997.2 K3.3 M
Slightly volatile
Selling General Administrative13.1 M20.4 M5.9 M
Slightly volatile
Other Operating Expenses40 M79.2 M21.3 M
Slightly volatile
Research Development34.3 M55.8 M15.9 M
Slightly volatile
Total Operating Expenses47.3 M76.2 M21.6 M
Slightly volatile
Cost Of Revenue826.4 K1.3 M332.2 K
Slightly volatile
Net Interest IncomeM5.1 M1.5 M
Slightly volatile
Interest IncomeM5.1 M1.5 M
Slightly volatile
Selling And Marketing Expenses886.4 K997.2 K1.1 M
Slightly volatile

Jasper Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.3 M6.6 M1.3 M
Slightly volatile
Begin Period Cash Flow47.4 M87.3 M19.1 M
Slightly volatile
Total Cash From Financing Activities53.2 M47.9 M37.9 M
Slightly volatile
End Period Cash Flow60.6 M72.1 M39.7 M
Slightly volatile
Total Cashflows From Investing Activities158.7 K178.5 K194.6 K
Slightly volatile
Depreciation847.9 K1.4 M307 K
Slightly volatile
Issuance Of Capital Stock59.9 M47.2 M27.8 M
Slightly volatile
Other Cashflows From Investing Activities17.1 K18 K142.3 K
Slightly volatile
Change To Netincome4.7 M5.3 M5.8 M
Slightly volatile
Change To Liabilities126.5 K142.3 K155.1 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.380.4024.9311
Slightly volatile
Payables Turnover0.230.240.1116
Slightly volatile
Cash Per Share4.674.911755.6451
Slightly volatile
Days Payables Outstanding1.5 K1.6 K17.4 K
Slightly volatile
Income Quality0.660.87840.5742
Slightly volatile
Net Debt To EBITDA0.870.915961.7372
Slightly volatile
Current Ratio8.774.975511.2024
Slightly volatile
Capex Per Share0.0360.03781.6143
Slightly volatile
Interest Debt Per Share0.120.12434.2824
Slightly volatile
Debt To Assets0.02160.02270.059
Slightly volatile
Price Earnings To Growth Ratio0.180.170.0686
Slightly volatile
Days Of Payables Outstanding1.5 K1.6 K17.4 K
Slightly volatile
Ebt Per Ebit1.121.11.0542
Very volatile
Effective Tax Rate0.02110.02220.0403
Slightly volatile
Long Term Debt To Capitalization0.00930.01040.0114
Slightly volatile
Quick Ratio8.784.975511.2058
Slightly volatile
Net Income Per E B T0.640.880.7832
Very volatile
Cash Ratio8.484.701511.0884
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00881.0632
Slightly volatile
Debt Ratio0.02160.02270.059
Slightly volatile

Jasper Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap294.7 M280.6 M123.6 M
Slightly volatile

Jasper Fundamental Market Drivers

Cash And Short Term Investments71.6 M

About Jasper Therapeutics Financial Statements

Jasper Therapeutics investors use historical fundamental indicators, such as Jasper Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jasper Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2.2 M
Cost Of Revenue1.3 M826.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.